11/26
02:11 pm
lgnd
Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
07:04 pm
lgnd
How Ligand Pharmaceuticals' Strong Q3 Results and Raised Guidance May Impact LGND Investors [Yahoo! Finance]
Medium
Report
How Ligand Pharmaceuticals' Strong Q3 Results and Raised Guidance May Impact LGND Investors [Yahoo! Finance]
11/19
08:17 am
lgnd
What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? [Yahoo! Finance]
Low
Report
What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? [Yahoo! Finance]
11/18
08:13 am
lgnd
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year [Yahoo! Finance]
Medium
Report
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year [Yahoo! Finance]
11/14
01:15 pm
lgnd
Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
10:13 am
lgnd
Ligand Pharmaceuticals: Superb Q3/2025 With Second Guidance Raise Heralds Good Things To Come [Seeking Alpha]
Medium
Report
Ligand Pharmaceuticals: Superb Q3/2025 With Second Guidance Raise Heralds Good Things To Come [Seeking Alpha]
11/10
11:05 am
lgnd
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at Royal Bank Of Canada from $185.00 to $234.00. They now have an "outperform" rating on the stock.
Medium
Report
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at Royal Bank Of Canada from $185.00 to $234.00. They now have an "outperform" rating on the stock.
11/10
05:53 am
lgnd
Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer [Yahoo! Finance]
Low
Report
Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer [Yahoo! Finance]
11/10
01:16 am
lgnd
Ligand Pharmaceuticals (NASDAQ:LGND) was upgraded by analysts at
Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
Medium
Report
Ligand Pharmaceuticals (NASDAQ:LGND) was upgraded by analysts at
Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
11/7
06:09 pm
lgnd
Ligand (LGND) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Ligand (LGND) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/7
11:09 am
lgnd
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at Benchmark Co. from $175.00 to $220.00. They now have a "buy" rating on the stock.
Low
Report
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at Benchmark Co. from $175.00 to $220.00. They now have a "buy" rating on the stock.
11/6
02:03 pm
lgnd
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at HC Wainwright from $206.00 to $231.00. They now have a "buy" rating on the stock.
Low
Report
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at HC Wainwright from $206.00 to $231.00. They now have a "buy" rating on the stock.
11/6
07:23 am
lgnd
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance [Yahoo! Finance]
Low
Report
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance [Yahoo! Finance]
11/6
07:00 am
lgnd
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
Medium
Report
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
11/3
11:03 am
lgnd
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $190.00 to $250.00. They now have an "outperform" rating on the stock.
Low
Report
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $190.00 to $250.00. They now have an "outperform" rating on the stock.
10/30
08:12 pm
lgnd
Ligand to Participate in November Investor Conferences [Yahoo! Finance]
Low
Report
Ligand to Participate in November Investor Conferences [Yahoo! Finance]
10/30
04:01 pm
lgnd
Ligand to Participate in November Investor Conferences
Low
Report
Ligand to Participate in November Investor Conferences
10/23
07:00 am
lgnd
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025
Low
Report
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025
10/16
07:00 am
lgnd
Ligand to Host Investor Day on December 9, 2025
Low
Report
Ligand to Host Investor Day on December 9, 2025
10/9
07:26 am
lgnd
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients [Yahoo! Finance]
Low
Report
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients [Yahoo! Finance]
10/9
07:00 am
lgnd
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
Low
Report
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
9/25
03:17 am
lgnd
Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292 [Yahoo! Finance]
Low
Report
Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292 [Yahoo! Finance]